SCHEMBL1790852

SCHEMBL1790852

Nn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA1A P35348 10/20 0.60
▸ HRH1 P35367 10/20 0.60
▸ ADRA1B P35368 10/20 0.60
▸ HRH3 Q9Y5N1 5/20 0.57
▸ KCNH2 Q12809 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ ABCB1 P08183 2/20 0.53
▸ ADRA2A P08913 2/20 0.52
▸ CHRM1 P11229 2/20 0.52
▸ ADRA2B P18089 2/20 0.52
▸ HTR2A P28223 2/20 0.52
▸ DRD3 P35462 2/20 0.52
▸ CHRM2 P08172 1/20 0.52
▸ ADRB1 P08588 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ GABRA1 P14867 1/20 0.52
▸ ADRA2C P18825 1/20 0.52
▸ SLC6A2 P23975 1/20 0.52
▸ HTR2C P28335 1/20 0.52
▸ SLC6A4 P31645 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1787363 0.88 TSHR (0.61) ADRA1AHRH1ADRA1BHRH3LMNA
SCHEMBL13720704 0.84 MEN1 (0.50) SMN1; SMN2TSHR
SCHEMBL13721057 0.83 ADRA1A (0.44) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL2819033 0.81 ADRA1A (0.72) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL1790428 0.74 ADRA1A (0.51) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL2819044 0.74 ADRA1A (0.66) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL30795062 0.74 ADRA1A (0.51) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL1789226 0.74 NPSR1 (0.64) LMNACYP2D6CYP3A4
SCHEMBL2990937 0.73 ABCB1 (0.92) ADRA1AHRH1ADRA1BHRH3KCNH2
SCHEMBL13890824 0.73 HRH1 (0.72) ADRA1AHRH1ADRA1BHRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 — — US disclosed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 — — EP disclosed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 — — WO disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 ADRA1A 260/4885HRH1 597/4885ADRA1B 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback